Ratio Therapeutics

Boston-based clinical-stage biopharmaceutical company developing targeted radiopharmaceuticals (radiotherapeutics) for cancer, including lead asset [Ac-225]RTX-2358; closed a $70 million Series C in 2026 with Duquesne Family Office, Bristol Myers Squibb, Catalio Capital, Eli Lilly, and Wasatch Group, bringing total capital raised to over $240 million.